TimesSquare Mid Cap Growth Strategy’s recent addition of Insmed (INSM) marks a deliberate pivot toward the biotech arena, a sector that has historically delivered outsized returns for investors willing to accept higher volatility. Insmed’s focus on rare‑disease therapeutics and its pipeline of promising candidates likely convinced the fund’s managers that the company’s growth trajectory aligns with the strategy’s mandate for mid‑cap, high‑potential plays.

For retail crypto enthusiasts, this development underscores a key